Full Text View
Tabular View
No Study Results Posted
Related Studies
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
This study has been terminated.
( Study DAR-312 did not meet its primary co-endpoints. )
Study NCT00389675   Information provided by Gilead Sciences

First Received on October 17, 2006.   Last Updated on March 23, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Additional drug interventions recognized in this trial
Antihypertensive Agents
Guanfacine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Gilead Sciences


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services